CyDex, Inc.

Hovione enters drug-development alliance for potential new products

Published in Biotech Law Weekly, July 23rd, 2004

Hovione, an international pharmaceutical fine chemicals company, and CyDex, Inc., which is creating new pharmaceutical products through drug-delivery technologies, announced an alliance to develop and commercialize improved formulations of drugs that are off-patent or soon will be off-patent.

The collaboration will use Captisol, a proven technology from CyDex, to develop formulations offering advantages such as improved bioavailability, dissolution, and stability. The companies agreed to develop Captisol-enabled formulations of six drugs initially but, for competitive reasons, did not announce the products.

Hovione's CEO, Guy Villax, commented, "We...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2004-07-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry